Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice
The 31st Conference on Retroviruses and Opportunistic Infections (CROI) took place between the 3rd–6th March 2024 onsite in Denver, Colorado, USA and online. As one of the major meetings in the field of HIV Medicine, some of the communications presented there have the potential to impact future clin...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | CMI Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950590924000064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344374519889920 |
|---|---|
| author | Jasmini Alagaratnam Laura I. Levi Kathrin van Bremen Andrea Mastrangelo Juan Ambrosioni |
| author_facet | Jasmini Alagaratnam Laura I. Levi Kathrin van Bremen Andrea Mastrangelo Juan Ambrosioni |
| author_sort | Jasmini Alagaratnam |
| collection | DOAJ |
| description | The 31st Conference on Retroviruses and Opportunistic Infections (CROI) took place between the 3rd–6th March 2024 onsite in Denver, Colorado, USA and online. As one of the major meetings in the field of HIV Medicine, some of the communications presented there have the potential to impact future clinical practice. In this concise report, we have highlighted some abstracts that may soon drive changes in the management of HIV infection and associated conditions. This document focusses on clinical research in adults; basic science and epidemiological abstracts are not covered here. Relevant communications widening the spectrum of currently available and in late-stage development long-acting injectable and oral antiretrovirals were presented. These included presentations reporting a wider use of long-acting injectable cabotegravir and rilpivirine in previously under-researched subpopulations and weekly oral administration of lenacapavir and islatravir. In the field of HIV-related comorbidities, cardiovascular and metabolic risks were highlighted in communications reporting semaglutide use in persons with HIV and lipohypertrophy and further results from sub-studies within the REPRIEVE trial. Several communications addressed the topic of post-exposure prophylaxis for sexually transmitted infection, including the open-label extension of the DoxyPEP trial and the final results of the DOXYVAC trial. In addition, updates on an Mpox outbreak, cryptococcal meningitis treatment and new vaccination strategies for Hepatitis B vaccine non-responders were also presented. |
| format | Article |
| id | doaj-art-e7a2bf071211438ea970dee1fff79654 |
| institution | Kabale University |
| issn | 2950-5909 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | CMI Communications |
| spelling | doaj-art-e7a2bf071211438ea970dee1fff796542025-08-20T03:42:40ZengElsevierCMI Communications2950-59092024-06-011110000610.1016/j.cmicom.2024.100006Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practiceJasmini Alagaratnam0Laura I. Levi1Kathrin van Bremen2Andrea Mastrangelo3Juan Ambrosioni4Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK; Section of Virology, Department of Infectious Disease, Imperial College London, London, UKDepartment of Infectious Diseases, St-Louis and Lariboisière Hospitals, APHP, University of Paris Cité, Paris, FranceMVZ Innere Medizin, Cologne, GermanyAllergology and Immunology Department, Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne, SwitzerlandHIV Unit, Infectious Diseases Service, Hospital Clinic-Fundació de Recerca Clinic Barcelona – Institut de investigacions Biomediques August Pi i Sunyer, Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain; Corresponding author at: HIV Unit, Infectious Disease Service, Hospital Clinic-Fundació de Recerca Clinic Barcelona – Institut de investigacions Biomediques August Pi i Sunyer, Villarroel 170, 08036, Barcelona, Spain.The 31st Conference on Retroviruses and Opportunistic Infections (CROI) took place between the 3rd–6th March 2024 onsite in Denver, Colorado, USA and online. As one of the major meetings in the field of HIV Medicine, some of the communications presented there have the potential to impact future clinical practice. In this concise report, we have highlighted some abstracts that may soon drive changes in the management of HIV infection and associated conditions. This document focusses on clinical research in adults; basic science and epidemiological abstracts are not covered here. Relevant communications widening the spectrum of currently available and in late-stage development long-acting injectable and oral antiretrovirals were presented. These included presentations reporting a wider use of long-acting injectable cabotegravir and rilpivirine in previously under-researched subpopulations and weekly oral administration of lenacapavir and islatravir. In the field of HIV-related comorbidities, cardiovascular and metabolic risks were highlighted in communications reporting semaglutide use in persons with HIV and lipohypertrophy and further results from sub-studies within the REPRIEVE trial. Several communications addressed the topic of post-exposure prophylaxis for sexually transmitted infection, including the open-label extension of the DoxyPEP trial and the final results of the DOXYVAC trial. In addition, updates on an Mpox outbreak, cryptococcal meningitis treatment and new vaccination strategies for Hepatitis B vaccine non-responders were also presented.http://www.sciencedirect.com/science/article/pii/S2950590924000064CROI 2024HIVantiretroviral therapyARTOpportunistic infectionsco-infections |
| spellingShingle | Jasmini Alagaratnam Laura I. Levi Kathrin van Bremen Andrea Mastrangelo Juan Ambrosioni Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice CMI Communications CROI 2024 HIV antiretroviral therapy ART Opportunistic infections co-infections |
| title | Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice |
| title_full | Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice |
| title_fullStr | Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice |
| title_full_unstemmed | Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice |
| title_short | Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice |
| title_sort | highlights from the 31st croi key communications with potential impact on future hiv clinical practice |
| topic | CROI 2024 HIV antiretroviral therapy ART Opportunistic infections co-infections |
| url | http://www.sciencedirect.com/science/article/pii/S2950590924000064 |
| work_keys_str_mv | AT jasminialagaratnam highlightsfromthe31stcroikeycommunicationswithpotentialimpactonfuturehivclinicalpractice AT laurailevi highlightsfromthe31stcroikeycommunicationswithpotentialimpactonfuturehivclinicalpractice AT kathrinvanbremen highlightsfromthe31stcroikeycommunicationswithpotentialimpactonfuturehivclinicalpractice AT andreamastrangelo highlightsfromthe31stcroikeycommunicationswithpotentialimpactonfuturehivclinicalpractice AT juanambrosioni highlightsfromthe31stcroikeycommunicationswithpotentialimpactonfuturehivclinicalpractice |